PIK3CB and acute myeloid leukemia: Interestingly, Nepstad, et al. characterized metabolic differences between primary AML cells sensitive and resistant to PI3K/Akt/mTOR inhibitors, including rapamycin, tracing them among glutamine and lipid metabolism [42].